Cingulate (CING) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual Meeting scheduled for June 10, 2025, to be held virtually; record date is April 14, 2025.
Key proposals include director election, auditor ratification, equity plan amendment, reverse stock split, and potential adjournment.
Board recommends voting FOR all proposals.
Voting matters and shareholder proposals
Election of Peter J. Werth as Class I director for a term expiring in 2028.
Ratification of KPMG LLP as independent auditor for 2025.
Amendment to the 2021 Omnibus Equity Incentive Plan to increase authorized shares by 800,000 to 1,141,826.
Approval of a reverse stock split at a ratio between 1:2 and 1:25, at Board's discretion, any time before June 2026.
Approval to adjourn the meeting if more time is needed to solicit votes.
Board of directors and corporate governance
Board consists of five members divided into three classes; all directors attended at least 75% of meetings in 2024.
Three standing committees: Audit, Compensation, and Nominating & Corporate Governance, all comprised of independent directors.
Board leadership structure combines CEO and Chairman roles; no Lead Independent Director currently.
Board regularly reviews risk, succession planning, and self-evaluations.
Latest events from Cingulate
- Shelf registration enables flexible securities issuance; auditor consent updated.CING
Registration filing23 Mar 2026 - Up to 3.5M shares may be sold to Lincoln Park for up to $25M to fund CNS drug development.CING
Registration filing20 Mar 2026 - Beneficial ownership table updated to include a 5% stockholder and clarify voting procedures.CING
Proxy Filing18 Mar 2026 - 2025 net loss widened to $22.4M as CTx-1301 advanced toward FDA review and $12M was raised.CING
Q4 202518 Mar 2026 - Approval sought for stock issuance and board changes following a $12M private placement.CING
Proxy Filing2 Mar 2026 - Approval sought for major equity issuance and board changes following a $12M private placement.CING
Proxy Filing18 Feb 2026 - Biopharma targets ADHD market with $200M shelf registration amid financial uncertainty.CING
Registration Filing12 Jan 2026 - Registering 6.63M shares for resale tied to ADHD drug warrants, with proceeds for operations.CING
Registration Filing16 Dec 2025 - Shareholders to vote on issuing new shares from warrants, potentially diluting holdings by 20%.CING
Proxy Filing2 Dec 2025